The U.S. Food and Drug Administration (FDA), under the direction of Health and Human Services Secretary Robert F. Kennedy, Jr ...

An audit by the State Comptroller's Office found the lab allegedly abused Medicaid program resources. The lab defended itself ...

This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with ...

The FDA on Thursday approved Fabhalta (iptacopan) to treat complement 3 glomerulopathy (CG3), a progressive, ultrarare kidney ...

Alnylam Pharmaceuticals' shares rose more than 10% on Friday after the drugmaker secured U.S. approval for its heart disease drug, setting the stage for the 23-year-old biotech's next phase of growth.

The label expansion couls help J&J establish Tremfya as a successor to Stelara, which is now facing a growing biosimilar ...

Fosamax further defines the obligation of drug manufacturers to present clear, unambiguous, and accurate information to the ...

Angel Del Villar is expected to face testimony from his former label star Gerardo Ortiz, who prosecutors say took a plea deal ...

Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G) Fabhalta is the only oral alternative complement pathway ...

Wyoming's Governor Mark Gordon has signed ten new laws, modernizing legislation on prostitution, medical prescriptions, and ...

An experimental drug appears to reduce the risk of Alzheimer's-related dementia in people destined to develop the disease in their 30s, 40s or 50s, according to the results of a new study. The ...

In a move to expand its portfolio beyond antibiotics, Paratek Pharmaceuticals has bought out Optinose and its chronic ...